Mitchell E. Taub

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

Joe Bentz, Michael O′Connor, Dallas Bednarczyk et al. · Drug Metabolism and Disposition · 2013 · 147 citations · Full text

FUNCTIONAL ASSESSMENT OF MULTIPLE P-GLYCOPROTEIN (P-GP) PROBE SUBSTRATES: INFLUENCE OF CELL LINE AND MODULATOR CONCENTRATION ON P-GP ACTIVITY

Mitchell E. Taub, Lalitha Podila, Diane Ely et al. · Drug Metabolism and Disposition · 2005 · 124 citations

Optimized conditions for MDCK permeability and turbidimetric solubility studies using compounds representative of BCS classes I–IV

Mitchell E. Taub, Lisbeth Langholz Kristensen · European Journal of Pharmaceutical Sciences · 2002 · 76 citations

Chemical Engineering, Engineering, Mdck Permeability +6

Differential Selectivity of Efflux Transporter Inhibitors in Caco-2 and MDCK–MDR1 Monolayers: A Strategy to Assess the Interaction of a New Chemical Entity with P-gp, BCRP, and MRP2

Kirsten Mease, Rucha Sane, Lalitha Podila et al. · Journal of Pharmaceutical Sciences · 2012 · 73 citations

Molecular Pharmacology, Mdck–mdr1 Monolayers, Drug Target +11

Digoxin Is Not a Substrate for Organic Anion-Transporting Polypeptide Transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but Is a Substrate for a Sodium-Dependent Transporter Expressed in HEK293 Cells

Mitchell E. Taub, Kirsten Mease, Rucha Sane et al. · Drug Metabolism and Disposition · 2011 · 69 citations